These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 21460437)

  • 1. Membrane anchored and lipid raft targeted β-secretase inhibitors for Alzheimer's disease therapy.
    Ben Halima S; Rajendran L
    J Alzheimers Dis; 2011; 24 Suppl 2():143-52. PubMed ID: 21460437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting.
    Rajendran L; Schneider A; Schlechtingen G; Weidlich S; Ries J; Braxmeier T; Schwille P; Schulz JB; Schroeder C; Simons M; Jennings G; Knölker HJ; Simons K
    Science; 2008 Apr; 320(5875):520-3. PubMed ID: 18436784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of sulindac sulfide on the membrane architecture and the activity of gamma-secretase.
    Gamerdinger M; Clement AB; Behl C
    Neuropharmacology; 2008 May; 54(6):998-1005. PubMed ID: 18359496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting ADAM10 to lipid rafts in neuroblastoma SH-SY5Y cells impairs amyloidogenic processing of the amyloid precursor protein.
    Harris B; Pereira I; Parkin E
    Brain Res; 2009 Nov; 1296():203-15. PubMed ID: 19679113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity.
    Yan R; Bienkowski MJ; Shuck ME; Miao H; Tory MC; Pauley AM; Brashier JR; Stratman NC; Mathews WR; Buhl AE; Carter DB; Tomasselli AG; Parodi LA; Heinrikson RL; Gurney ME
    Nature; 1999 Dec; 402(6761):533-7. PubMed ID: 10591213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts.
    Ehehalt R; Keller P; Haass C; Thiele C; Simons K
    J Cell Biol; 2003 Jan; 160(1):113-23. PubMed ID: 12515826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge.
    Citron M
    Trends Pharmacol Sci; 2004 Feb; 25(2):92-7. PubMed ID: 15102495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secretase inhibitors and modulators for Alzheimer's disease treatment.
    Tomita T
    Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.
    Sevalle J; Ayral E; Hernandez JF; Martinez J; Checler F
    J Neurochem; 2009 Jul; 110(1):275-83. PubMed ID: 19457123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-secretase as a target for the treatment of Alzheimer's disease.
    Citron M
    J Neurosci Res; 2002 Nov; 70(3):373-9. PubMed ID: 12391600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The structure and function of Alzheimer's gamma secretase enzyme complex.
    Krishnaswamy S; Verdile G; Groth D; Kanyenda L; Martins RN
    Crit Rev Clin Lab Sci; 2009; 46(5-6):282-301. PubMed ID: 19958215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
    Pollack SJ; Lewis H
    Curr Opin Investig Drugs; 2005 Jan; 6(1):35-47. PubMed ID: 15675602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural optimization of a CXCR2-directed antagonist that indirectly inhibits gamma-secretase and reduces Abeta.
    Bakshi P; Jin C; Broutin P; Berhane B; Reed J; Mullan M
    Bioorg Med Chem; 2009 Dec; 17(23):8102-12. PubMed ID: 19853461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caveolin-1 regulates γ-secretase-mediated AβPP processing by modulating spatial distribution of γ-secretase in membrane.
    Kapoor A; Hsu WM; Wang BJ; Wu GH; Lin TY; Lee SJ; Yen CT; Liang SM; Liao YF
    J Alzheimers Dis; 2010; 22(2):423-42. PubMed ID: 20847442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in gamma-secretase modulation.
    Pissarnitski D
    Curr Opin Drug Discov Devel; 2007 Jul; 10(4):392-402. PubMed ID: 17659480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active gamma-secretase is localized to detergent-resistant membranes in human brain.
    Hur JY; Welander H; Behbahani H; Aoki M; Frånberg J; Winblad B; Frykman S; Tjernberg LO
    FEBS J; 2008 Mar; 275(6):1174-87. PubMed ID: 18266764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are γ-secretase inhibitors detrimental for Alzheimer's disease patients?
    Ross JS; Imbimbo BP
    J Alzheimers Dis; 2010; 22(2):401-4. PubMed ID: 21149978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of the lipidation of beta-secretase by statins.
    Parsons RB; Farrant JK; Price GC; Subramaniam D; Austen BM
    Biochem Soc Trans; 2007 Jun; 35(Pt 3):577-82. PubMed ID: 17511656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. gamma-Secretase as a target for drug intervention in Alzheimer's disease.
    Harrison T; Churcher I; Beher D
    Curr Opin Drug Discov Devel; 2004 Sep; 7(5):709-19. PubMed ID: 15503873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.